Emergence of Klebsiella pneumoniae carbapenemase-producing bacteria

Southern Medical Journal

Volumn 104, Issue 1, 2011, Pages 40-45

  Arnold, Ryan S ^a   Thom, Kerri A ^a   Sharma, Saarika ^a   Phillips, Michael ^a   Kristie Johnson, J ^a   Morgan, Daniel J ^a  

^a NONE

Author keywords

carbapenem resistant; Enterobacteriaceae; Klebsiella multi drug resistant

Indexed keywords

ACHN 490; AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; BACTERIAL ENZYME; BETA LACTAM ANTIBIOTIC; CARBAPENEM DERIVATIVE; CARBAPENEMASE; CEPHALOSPORIN DERIVATIVE; CLAVULANIC ACID; GENTAMICIN; IMIPENEM; MEROPENEM; MONOBACTAM DERIVATIVE; NAB 739; NAB 740; NXL 104; OMADACYCLINE; PENICILLIN DERIVATIVE; POLYMYXIN; POLYMYXIN B; POLYMYXIN DERIVATIVE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TIGECYCLINE; UNCLASSIFIED DRUG;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL THERAPY; ARTICLE; BACTERIAL COLONIZATION; BACTERIAL STRAIN; BACTERIAL TRANSMISSION; BACTERICIDAL ACTIVITY; BACTERIUM DETECTION; BACTERIUM ISOLATE; CARBAPENEMASE PRODUCING BACTERIUM; CLINICAL FEATURE; DRUG EFFICACY; EPIDEMIOLOGICAL DATA; HOSPITAL INFECTION; HUMAN; INFECTION CONTROL; INTENSIVE CARE UNIT; KLEBSIELLA PNEUMONIAE; KLEBSIELLA PNEUMONIAE INFECTION; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; MULTIDRUG RESISTANCE; NEPHROTOXICITY; NEUROTOXICITY; NONHUMAN; UNITED STATES;

ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; BACTERIOLOGICAL TECHNIQUES; BETA-LACTAMASES; DIAGNOSIS, DIFFERENTIAL; HUMANS; KLEBSIELLA INFECTIONS; KLEBSIELLA PNEUMONIAE; METALLOPROTEINS;

EID: 78650883759     PISSN: 00384348     EISSN: None     Source Type: Journal    
DOI: 10.1097/SMJ.0b013e3181fd7d5a     Document Type: Article

References (43)

1. Paterson DL, Bonomo RA. Extended-spectrum beta-lactamases: a clinical update. Clin Microbiol Rev 2005;18:657-686.
2. Rhomberg PR, Jones RN. Summary trends for the Meropenem Yearly Susceptibility Test Information Collection Program: a 10-year experience in the United States (1999-2008). Diagn Microbiol Infect Dis 2009;65:414-426.
3. Yigit H, Queenan AM, Anderson GJ, et al. Novel carbapenem-hydro-lyzing beta-lactamase, KPC-1, from a carbapenem-resistant strain of Klebsiella pneumoniae. Antimicrob Agents Chemother 2001;45:1151-1161.
4. Lee J, Patel G, Huprikar S, et al. Decreased susceptibility to polymyxin B during treatment of carbapenem-resistant Klebsiella pneumoniae infection. J Clin Microbiol 2009;47:1611-1612.
5. Kitchel B, Rasheed JK, Patel JB, et al. Molecular epidemiology of KPC-producing Klebsiella pneumoniae isolates in the United States: clonal expansion of multilocus sequence type 258. Antimicrob Agents Chemother 2009;53:3365-3370.
6. Centers for Disease Control and Prevention (CDC). Guidance for control of infections with carbapenem-resistant or carbapenemase-producing En-terobacteriaceae in acute care facilities. MMWR Morb Mortal Wkly Rep 2009;58:256-260.
7. Bratu S, Landman D, Haag R, et al. Rapid spread of carbapenem-resis-tant Klebsiella pneumoniae in New York City: a new threat to our antibiotic armamentarium. Arch Intern Med 2005;165:1430-1435.
8. Bratu S, Tolaney P, Karumudi U, et al. Carbapenemase-producing Kleb-siella pneumoniae in Brooklyn, NY: molecular epidemiology and in vitro activity of polymyxin B and other agents. J Antimicrob Chemother 2005;56:128-132.
9. Phillips M, Sharma S. Clinical Outcomes of Infections Caused by KPC-Producing Organisms. Bethesda, NIH Workshop on ESKAPE Pathogens, 2009.
10. Naas T, Nordmann P, Vedel G, et al. Plasmid-mediated carbapenem- hydrolyzing beta-lactamase KPC in a Klebsiella pneumoniae isolate in France. Antimicrob Agents Chemother 2005;49:4423-4424.
11. Leavitt A, Navon-Venezia S, Chmelnitsky I, et al. Emergence of KPC-2 and KPC-3 in carbapenem-resistant Klebsiella pneumoniae strains in an Israeli hospital. Antimicrob Agents Chemother 2007;51:3026-3029.
12. Osterblad M, Kirveskari J, Koskela S, et al. First isolations of KPC-2-carrying ST258 Klebsiella pneumoniae strains in Finland, June and August 2009. Euro Surveill 2009;14:pii:19349.
13. Endimiani A, Hujer AM, Perez F, et al. Characterization of blaKPC-containing Klebsiella pneumoniae isolates detected in different institutions in the Eastern USA. J Antimicrob Chemother 2009;63:427-437.
14. Nordmann P, Cuzon G, Naas T. The real threat of Klebsiella pneu-moniae carbapenemase-producing bacteria. Lancet Infect Dis 2009;9: 228-236.
15. Marchaim D, Navon-Venezia S, Schwaber MJ, et al. Isolation of imi-penem-resistant Enterobacter species: emergence of KPC-2 carbapen-emase, molecular characterization, epidemiology, and outcomes. Anti-microb Agents Chemother 2008;52:1413-1418.
16. Weisenberg SA, Morgan DJ, Espinal-Witter R, et al. Clinical outcomes of patients with Klebsiella pneumoniae carbapenemase-producing K. pneumoniae after treatment with imipenem or meropenem. Diagn Mi-crobiol Infect Dis 2009;64:233-235.
17. Anderson KF, Lonsway DR, Rasheed JK, et al. Evaluation of methods to identify the Klebsiella pneumoniae carbapenemase in Enterobacteri-aceae. J Clin Microbiol 2007;45:2723-2725.
18. Samra Z, Bahar J, Madar-Shapiro L, et al. Evaluation of CHROMagar KPC for rapid detection of carbapenem-resistant Enterobacteriaceae. J Clin Microbiol 2008;46:3110-3111.
19. Nadkarni AS, Schliep T, Khan L, et al. Cluster of bloodstream infections caused by KPC-2 carbapenemase-producing Klebsiella pneumoniae in Manhattan. Am J Infect Control 2009;37:121-126.
20. Gasink LB, Edelstein PH, Lautenbach E, et al. Risk factors and clinical impact of Klebsiella pneumoniae carbapenemase-producing K. pneu-moniae. Infect Control Hosp Epidemiol 2009;30:1180-1185.
21. Patel G, Huprikar S, Factor SH, et al. Outcomes of carbapenem-resistant Klebsiella pneumoniae infection and the impact of antimicrobial and ad-junctive therapies. Infect Control Hosp Epidemiol 2008;29:1099-1106.
22. Maltezou HC, Giakkoupi P, Maragos A, et al. Outbreak of infections due to KPC-2 producing Klebsiella pneumoniae in a hospital in Crete (Greece). J Infect 2009;58:213-219.
23. Borer A, Saidel-Odes L, Riesenberg K, et al. Attributable mortality rate for carbapenem-resistant Klebsiella pneumoniae bacteremia. Infect Control Hosp Epidemiol 2009;30:972-976.
24. Mathers AJ, Cox HL, Bonatti H, et al. Fatal cross infection by carbap-enem-resistant Klebsiella in two liver transplant recipients. Transpl Infect Dis 2009;11:257-265.
25. Hidron AI, Edwards JR, Patel J, et al; National Healthcare Safety Network Team; Participating National Healthcare Safety Network Facilities. NSHN annual update: antimicrobial-resistant pathogens associated with healthcare-associated infections: annual summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006-2007. Infect Control Hosp Epidemiol 2008;29: 996-1011.
26. Kochar S, Sheard T, Sharma R, et al. Success of an infection control program to reduce the spread of carbapenem-resistant Klebsiella pneu-moniae. Infect Control Hosp Epidemiol 2009;30:447-452.
27. Endiminai A, Depasquale JM, Forero S, et al. Emergence of blaKPC-containing Klebsiella pneumoniae in a long-term acute care hospital: a new challenger to our healthcare system. J Antimicrob Chemother 2009; 4:1102-1110.
28. Munoz-Price LS, Hayden MK, Lolans K, et al. Successful control of an outbreak of Klebsiella pneumoniae at a long-term acute care hospital. Infect Control Hosp Epidemiol 2010;31:341-347.
29. Sakka SG, Glauner AK, Bulitta JB, et al. Population pharmacokinetics and pharmacodynamics of continuous versus short-term infusion of imi-penem-cilastin in critically ill patients in a randomized, controlled trial. Antimicrob Agents Chemother 2007;51:3304-3310.
30. Giamarellou H, Poulakou G. Multidrug-resistant gram-negative infections: what are the treatment options? Drugs 2009;69:1879-1901.
31. Petrosillo N, Ioannidou E, Falagas ME. Colistin monotherapy vs. combination therapy: evidence from microbiological, animal, and clinical studies. Clin Microbiol Infect 2008;14:816-827.
32. Castanheira M, Sader HS, Deshpande LM, et al. Antimicrobial activities of tigecycline and other broad-spectrum antimicrobials tested against serine carbapenemase- and metallo-beta-lactamase-producing Enter-obacteriaceae: report from the SENTRY antimicrobial surveillance program. Antimicrob Agents Chemother 2008;52:570-573.
33. Livermore DM, Hope R, Brick G, et al. Non-susceptibility trends among Enterobacteriaceae from bacteraemias in the UK and Ireland, 2001-06. J Antimicrob Chemother 2008;62(suppl 2):ii41-ii54.
34. Kelesidis T, Karageorgopoulos DE, Kelesidis I, et al. Tigecycline for the treatment of multidrug-resistant Enterobacteriaceae: a systematic review of the evidence from microbiological and clinical studies. J Anti-microb Chemother 2008;62:895-904.
35. Anthony KB, Fishman NO, Linkin DR, et al. Clinical and microbiological outcomes of serious infections with multidrug-resistant gram-negative organisms treated with tigecycline. Clin Infect Dis 2008;46:567-570.
36. Daly MW, Riddle DJ, Ledeboer NA, et al. Tigecycline for treatmnet of pneumonia and empyema caused by carbapenemase-producing Kleb-siella pneumoniae. Pharmacotherapy 2007;27:1052-1057.
37. Livermore DM. Has the era of untreatable infections arrived? J Antimi-crob Chemother 2009;64(suppl 1):i29-i36.
38. Endimiani A, Hujer KM, Hujer A, et al. ACHN-490, a neoglycoside with potent in vitro activity against multidrug-resistant Klebsiella pneu-moniae isolates. Antimicrob Agents Chemother 2009;53:4504-4507.
39. Eleman A, Rahimian J, Mandell W. Infection with panresistant Kleb-siella pneumoniae: a report of 2 cases and a brief review of the literature. Clin Infect Dis 2009;49:271-274.
40. Endimiani A, Patel G, Hujer KM, et al. In vitro activity of fosfomycin against blaKPC-containing Klebsiella pneumoniae isolates, including those nonsusceptible to tigecycline and/or colistin. Antimicrob Agents Chemother 2010;54:526-529.
41. Stachyra T, Levasseur P, Péchereau M, et al. In vitro activity of the {beta}-lactamase inhibitor NXL104 against KPC-2 carbapenemase and Enterobacteriaceae expressing KPC carbapenemases. J Antimicrob Che-mother 2009;64:326-329.
42. Livermore D, Mushtaq S, Warner M, et al. NXL104 combinations versus Enterocbacteriaceae with CTX-M extended-spectrum beta-lactama-ses and carbapenemases. J Antimicrob Chemother 2008;62:1053-1056.
43. Vaara M, Fox J, Loidl G, et al. Novel polymyxin derivatives carrying only three positive charges are effective antibacterial agents. Antimicrob Agents Chemother 2008;52:3229-3232.